Enhancing GAS6/AXL signaling as new neuroprotective and immunomodulatory strategy to tackle amyotrophic lateral sclerosis

Ended Project Grant Awarded Last action

Award ID
HT94252410247
Recipient
Awarding agency
Obligated
$789,903

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Italy

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of Defense's Defense Health Agency has awarded a $789,903 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Universita' Degli Studi DI Pavia in Italy. The grant, effective from September 1, 2024 through August 31, 2026, will fund research to enhance the GAS6/AXL signaling pathway as a potential neuroprotective and immunomodulatory strategy for tackling amyotrophic lateral sclerosis (ALS). As the prime awardee, Universita' Degli Studi DI Pavia has a history of conducting federal grant-funded research in areas such as naval operations, disease treatment, materials science, and other domains, often collaborating with US academic institutions as a subrecipient.

Quick answers

Who received award HT94252410247?

HT94252410247 was awarded to Universita' Degli Studi DI Pavia by Defense Health Agency (Department of Defense) on September 1, 2024.

How much is award HT94252410247 worth?

$789,903 has been obligated on HT94252410247.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login